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Purpose: To describe the clinical findings and long-term outcome of patients with chronic 
central serous chorioretinopathy (cCSC).
Materials and methods: This was a retrospective case series in 52 eyes of 36 patients 
with a follow-up period of at least 1 year. Extensive ophthalmic examination and a validated 
questionnaire concerning vision-related quality of life (National Eye Institute Visual Function 
Questionnaire [NEI-VFQ]-39) were analyzed.
Results: Mean visual acuity showed a significant decline over time of 0.16 logarithm of 
minimum angle of resolution ([logMAR] range: -0.22 to 1.3; P=0.009) after a mean follow-up 
period of 10.6 years. Also, patients reported lower vision-related quality of life based on the 
NEI-VFQ-39 for almost all categories compared to healthy controls. Macular atrophy was 
diagnosed more often on optical coherence tomography compared to other diagnostic entities. 
Retinal pigment epithelium detachments in the macula were documented on optical coherence 
tomography in 56% of the patients. A significant thinning of foveal thickness was measured over 
time compared to unaffected fellow eyes (P=0.002). On long-term follow-up, 13 eyes (37%) 
showed an increase in number of hot spots on fluorescein angiography.
Conclusion: This study indicates that cCSC is a progressive disease in many patients, causing 
a progressive decline in visual acuity, accompanied by lower reported vision-related quality of 
life. In deciding whether or not to treat, the progressive nature of cCSC should be taken into 
account in this relatively young and often still professionally active patient group.
Keywords: chronic central serous chorioretinopathy, micropulse laser, NEI-VFQ-39, PDT, 
vision-related quality of life
Introduction
Central serous chorioretinopathy (CSC) is characterized by fluid accumulation between 
the neuroretina and retinal pigment epithelium (RPE).1,2 It often affects the macula, 
leading to central vision loss, scotoma, metamorphopsia, and/or micropsia.1,2 The 
accumulation of subretinal fluid (SRF) results from leakage through a dysfunctional 
RPE with a disrupted outer blood–retina barrier. Dilation, congestion, and hyperper-
meability of the choriocapillaris and larger choroidal vessels appear to play a pivotal 
role in the pathogenesis of CSC.3–5 The etiology of CSC is unknown. Risk factors for 
CSC include the use of corticosteroids, Cushing’s disease, pregnancy, and male sex.2,6 
Recent studies have also found genetic associations.7,8
There are two main subtypes of CSC. Acute CSC is characterized by sudden 
vision loss, due to fluid leakage through a focal pinpoint leak in the RPE, often in 
association with a small RPE detachment.1,2 In most acute CSC patients, the SRF 
resolves spontaneously within 2–3 months.1 Visual acuity (VA) in these patients 
generally returns to (near-) normal levels.1 In the other main subtype, chronic CSC 
(cCSC), patients have more widespread atrophic RPE abnormalities, as well as more 
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extensive choroidal changes on fluorescein angiography (FA) 
and indocyanine green angiography (ICGA).1,2 In contrast to 
acute CSC, most patients with cCSC have more pronounced 
central vision loss, and often do not show a spontaneous 
resolution of SRF.2
Although cCSC is one of the most common forms of 
macular degeneration,1 relatively little is known about the 
long-term visual consequences in these patients. The aim of 
this study was to evaluate the clinical outcome of patients 
with cCSC and assess their vision-related quality of life to 
provide a more accurate prognosis to patients.
Materials and methods
Participants
Patients with cCSC and a follow-up of at least 1 year were 
included in this retrospective observational study. Subjects 
were recruited from the Department of Ophthalmology of Rad-
boud University Medical Center (Nijmegen, the Netherlands) 
and the Oxford Eye Hospital (Oxford, UK). All patients 
gave written informed consent for the use of their data for 
this retrospective study. The diagnosis of cCSC was defined 
as the presence of SRF longer than 3 months in at least one 
eye on optical coherence tomography (OCT), RPE window 
defects on FA with at least 1 “hot spot”, defined as indistinct 
hyperfluorescent area of leakage and/or diffuse leakage in the 
affected eye(s), and corresponding hyperfluorescent zones on 
ICGA when available. Patients with evidence of other retinal 
diagnoses at the first visit were excluded. This study adhered 
to the tenets of the Declaration of Helsinki, and approval 
for the study in Oxford was obtained from the Integrated 
Research Authority, Essex 2 Research Ethics Committee. 
The ethical approval for the study in Nijmegen was waived 
by Commissie Mensgebonden Onderzoek (CMO) of the 
Radboud University Medical Center in Nijmegen, as all clini-
cal data was obtained retrospectively and the questionnaire 
was found to be non-invasive and not personally sensitive 
for the study objects.
The following parameters, when available, were col-
lected from the medical records: VA, disease activity, 
duration of visual symptoms, (prior) use of corticosteroids, 
number of treatments, color fundus photography, OCT, 
FA, and ICGA. Only visits for which VA and informa-
tion about disease activity, defined as subfoveal fluid on 
OCT or (when OCT was not available) as stated by the 
ophthalmologist in the medical records, were included. 
Additionally, patients were asked to complete a validated 
questionnaire (Visual Function Questionnaire [VFQ]-39).9 
For all Dutch patients, a validated Dutch translation of this 
questionnaire was used.10
Clinical evaluation
Submacular RPE detachments, subfoveal SRF, change in 
submacular SRF accumulation, and retinal atrophy were 
scored on OCT. The number of hot spots, defined as indistinct 
hyperfluorescent areas of leakage, seen on FA and ICGA 
were registered. Evidence of RPE atrophy was assessed on 
FA and color fundus photography.
Central foveal thickness (CFT), defined as the distance 
between the outer part of the internal limiting membrane 
and the outer part of the external limiting membrane at the 
central fovea, of the first and the last available OCT scans was 
measured by two independent graders. Only patients who had 
follow-up imaging with spectral domain OCT (Spectralis™; 
Heidelberg Engineering, Heidelberg, Germany) were included 
in CFT measurements. The mean of the measurements of both 
graders was used for further analysis after no significant 
difference between the graders was confirmed by Student’s 
independent t-test (P.0.05). In selected patients, unaffected 
fellow eyes, defined as eyes in which no central lesions sus-
pect for cCSC were present, were included. The difference 
in CFT over time was compared between the affected and 
unaffected eyes using Student’s independent t-test.
Visual acuity
The VA of all first visits was compared to the VA of all last 
known visits using an independent-sample t-test. For the VA 
of the last visit, only patients with inactive disease, defined 
as absence of SRF on OCT, were included. Additionally, a 
Pearson’s correlation test was performed to determine if the 
number of episodes of active disease or the number of treat-
ments affected the overall change in VA when comparing 
the first visit to the last visit.
Vision-related quality of life
The scores of every individual subcategory of the VFQ-39 
were compared to the reference group, which was used for 
assessment in the original validation of the VFQ-39,9,21 using 
the independent-sample t-test. The original validation of the 
VFQ-39 analyzed the data of the reference group as being nor-
mally distributed; therefore, this study also chose this approach. 
A Pearson’s correlation test was performed to analyze if the 
VA at the end of follow-up was associated with VFQ-39 score. 
P,0.05 was considered statistically significant for all tests.
Results
Demographics
Demographic information is presented in Table 1. The 
mean number of episodes of active disease per eye was 
1.7 (range: 0–6). Each episode was defined as a presence 
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of documented SRF followed by a period of OCT-proven 
absence of SRF.
Clinical course
When the VA of the first and last visits was compared, exclud-
ing the 21 eyes (40%) with persistent subfoveal SRF at the 
final visit, a mean decline of 0.16 logarithm of minimum angle 
of resolution (logMAR; range: -0.22 to 1.3, P=0.009) was 
found after a mean follow-up period of 10.6 (range: 1.5–24) 
years. In the 21 eyes (40%) with persistent subfoveal SRF at 
the final visit, a mean decline of 0.22 logMAR (range: -0.35 
to 0.66, P=0.003) with a mean follow-up period of 4.5 (range: 
1–11) years was seen. In 11 of these 21 eyes (52%), the SRF 
was continuously present during follow-up. Neither the num-
ber of episodes of active disease nor number of treatments 
had a significant effect on overall change in VA.
Optical coherence tomography
An overview of OCT findings is displayed in Table 2 and 
Figure 1A–C. In the 13 eyes with a decrease in SRF, eight 
(62%) had received treatment. The seven eyes with an 
increase of SRF had not received treatment. In the eyes show-
ing fluctuating SRF accumulation, 18 (82%) had received 
treatment. The following treatments were performed: 
41 micropulse therapy, 23 photodynamic therapy (PDT), 
one argon-laser treatment, one anecortave acetate treatment, 
and nine anti-VEGF treatments.
In 14 eyes (24%), SRF was continuously present on OCT 
until the last follow-up. In this group, this was also the case 
in five eyes (36%) despite receiving treatment (micropulse 
therapy [52%], PDT [29%], anti-VEGF [14%], and argon-
laser treatment [5%]).
Posterior cystoid retinal degeneration, described previ-
ously by Piccolino et al, was seen in seven eyes of four 
patients (8%; Figure 1D–G).11 In three of these seven eyes, 
a lesion suspected to be choroidal neovascularization devel-
oped during follow-up. In three of seven eyes, the posterior 
cystoid retinal degeneration disappeared completely during 
follow-up, in two eyes this resolution occurred spontaneously, 
and in one eye it occurred after PDT (Figure 1H and I). The 
onset of posterior cystoid retinal degeneration was 2, 10, and 
16 years after the reported start of the cCSC in three of the 
four patients in whom this was recorded (Figure 1D–G).
In 21 eyes (41%) with SRF and six eyes without SRF, 
spectral domain OCT was available for evaluation of CFT 
on follow-up. CFT showed a mean decrease of 15.1 μm 
Table 1 Demographics of the study population
Parameter Nijmegen Oxford Total
Patients (affected eyes) 22 (33) 14 (19) 36 (52)
sex (male/female) 13/9 8/6 21/15
Mean age (years) 56.9 (range: 42–72) 56.3 (range: 39–81) 56.7 (range: 39–81)
Bilateral disease (patients) 11 (50%) 5 (36%) 16 (44%)
reported steroid use (patients) 6 (27%) 4 (29%) 10 (28%)
Mean follow-up (years) 9.8 (range: 1–24) 3.8 (range: 1–11) 7.4 (range: 1–24)
Mean number of treatments per eye 3.2 (range: 0–8) 0.1 (range: 0–1) 2.1 (range: 0–8)
Note: Patients were recruited from the Department of Ophthalmology of radboud University Medical Center (nijmegen, the netherlands) and the Oxford eye hospital 
(Oxford, UK).
Table 2 Overview of findings on optical coherence tomography and fluorescein angiography
Optical coherence tomography Fluorescein angiography
number of rPe detachments Number of hot spots at first visit (n=45)
0=23 eyes (44%) 1=13 eyes (29%)
$1=29 eyes (56%) 2=7 eyes (16%)
subfoveal srF $3=3 eyes (7%)
Yes =40 eyes (77%) Diffuse leakage =7 eyes (16%)
no =12 eyes (23%) no clear leakage =15 eyes (33%) 
Outer-photoreceptor-layer atrophy Change in number of hot spots (n=35)
Yes =24 eyes (49%) increase =13 eyes (37%)
no =28 eyes (51%) Decrease =9 eyes (26%)
Change in height of srF accumulation (n=49) no change =2 eyes (6%)
Decrease =13 (27%) new hot spota,b =2 eyes (6%)
increase =7 (14%) no clear hot spotc =9 eyes (26%)
no change =3 (6%)
Fluctuation =26 (53%)
Notes: aHot spot defined as indistinct hyperfluorescent area of leakage; bdisappearance of the original hot spot and appearance of a new hot spot; cno distinct hot spot at first visit.
Abbreviations: RPE, retinal pigment epithelium; SRF, subretinal fluid.
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(standard deviation: 17.7 μm) in eyes with SRF, whereas 
no significant change was seen in eyes without SRF. This 
difference in CFT was statistically significant (P=0.002).
Fluorescein angiography, indocyanine 
green angiography, and color fundus 
photography
Characteristics of hot spots of leakage on FA on follow-up are 
shown in Table 2. Of the nine eyes that showed a decrease in 
number of hot spots during follow-up, in seven the original hot 
spots disappeared after treatment, whereas the number of hot 
spots decreased spontaneously in the remaining two eyes. Over-
all, the mean number of hot spots at the first visit was 1 (range: 
0–4) compared to 1.7 (range: 0–7) at the last visit (Figure 2A 
and B). An increase in atrophic RPE changes on FA was seen 
in 14 eyes (41%) during a mean follow-up of 9.7 years (range: 
2–24 years). A classic “gravitational tract” was seen in eight 
eyes (15%), and was already present at the first visit in five eyes 
(Figure 2C and D). The other three eyes developed the gravita-
tional tract after approximately 2, 4, and 8 years, respectively.
When ICGA was available (in 28 eyes [54%]), hot spots 
and hyperfluorescent areas on ICGA in 27 eyes (96%), was 
Figure 1 imaging of two chronic central serous chorioretinopathy (cCsC) patients.
Notes: Images demonstrate characteristic findings in long-standing cCSC on optical coherence tomography (OCT) and fluorescein angiography (FA). (A–C) Fluctuating 
subretinal fluid (SRF) accumulation on OCT in the right eye of a patient, and typical subfoveal retinal pigment epithelium detachments. The time between scans A and B 
was 1 month, in which a clear decrease in srF occurred, and between scans B and C another 2 weeks elapsed, showing a spontaneous increase in srF. no therapeutic 
interventions had been performed between these visits. (D–G) Fa and OCT of the right and left eyes of a cCsC patient suffering from bilateral extensive cCsC. On Fa, a 
large area of hyperfluorescence can be seen, indicating advanced disease (D, E). OCT shows not only serous srF in the right eye but also bilateral central posterior cystoid 
degeneration, indicative of long-standing disease (F, G). This central posterior cystoid degeneration resolved spontaneously after a period of approximately 6 months (H, I).
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Figure 2 Abnormalities on fluorescein angiography (FA), indocyanine green angiography (ICGA), and fundus autofluorescence in chronic central serous chorioretinopathy.
Notes: (A, B) The appearance of “new” hot spots, highlighted by two arrows, on Fa during 4 years of follow-up. (C, D) The development of a gravitational tract was 
observed originating from the initial leakage area after 6 years of follow-up. (E, F) Examples of differences seen in the extent of the hyperfluorescence areas between FA 
(E) and iCga (F). The area depicted by the arrow shows clear hyperfluorescence on ICGA, but is not evident on the mid-phase FA. (G, H) iCga (H) shows small punctiform 
hyperfluorescent areas in addition to diffuse hyperfluorescence. The corresponding FA (G) of the same patient shows an area of hyperfluorescence that is significantly smaller 
than the area seen on iCga.
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compared with characteristics on FA that was performed on 
the same date. The overall hyperfluorescent area was larger 
on ICGA in eight eyes (30%), in eleven eyes (41%) the 
hyperfluorescent area had comparable size, in one eye (4%) 
the hyperfluorescent area was smaller on ICGA, and in eight 
eyes (30%) no clear hyperfluorescence was seen on ICGA 
to be compared (Figure 2E and F). In eleven eyes (39%), 
ICGA showed multiple small punctate hyperfluorescent 
spots, without clear evidence of a leaking hot spot focus 
(Figure 2G and H).
Color fundus photography was available at baseline in 
42 eyes (81%), and mild RPE atrophy in the macula was 
seen in 18 eyes (43%). Follow-up images were available 
for 31 eyes (74%), with a mean follow-up of 45 months 
(range: 1.5–87 months), and evidence of development and/or 
progression of RPE atrophy was present in 14 eyes (45%).
Quality of life
Patients of this cCSC cohort scored significantly less on the 
VFQ-39 questionnaire compared to the reference group on 
eight of the 12 subcategories (Table 3). Patients with a lower 
last recorded VA scored significantly lower on the following 
categories of the VFQ-39: general vision, near activities, 
distance activities, social functioning, mental health, role 
difficulties, dependence, and driving (Table 3).
Discussion
This study shows that cCSC is a progressive chorioretin-
opathy with a significant impact on VA and vision-related 
quality of life. Patients in this study cohort generally showed 
a progressive decline in VA, as well as a gradual decrease in 
CFT on OCT. Wang et al demonstrated in the pre-OCT era 
that persistence of SRF for more than 4 months can result 
in foveal atrophy.12 This permanent damage to photorecep-
tors and the RPE can explain the often-persistent visual 
complaints, even after resolution of SRF. The progressive 
nature of cCSC was demonstrated on FA, characterized by 
an increase of hyperfluorescent atrophic RPE changes and 
an increased number of hot spots during follow-up.
An interesting finding in this study were the small punc-
tate hyperfluorescent spots on ICGA (Figure 2H). Similar 
lesions were described by Tsujikawa et al.13 This group 
described small clusters, which were located within the 
center of the focal hyperfluorescent area on ICGA and thus 
thought to be very small leakage spots. In this study, no clear 
abnormalities corresponding to these lesions on ICGA could 
be identified on OCT. However, Lehmann et al identified 
similar hyperfluorescent lesions on ICGA that correlated 
with vascular dilations on en face enhanced-depth OCT.14 
In contrast to the lesions seen in this study, the lesions were 
always located under an area of SRF accumulation and/or 
RPE detachment. Additionally, a clinical and pathogenetic 
overlap between CSC and polypoidal choroidal vasculopathy 
may exist. Punctate hyperfluorescent spots on ICGA have 
also been identified in polypoidal choroidal vasculopathy, in 
which these lesions correlated with a thicker choroid.15 We 
thus hypothesize that these lesions may be focal vascular 
dilations in the choriocapillaris that fill on ICGA.
The blood flow in the choroid is among the highest in 
the human body, and the macular choriocapillaris is thicker, 
has a distinct lobular architecture, and higher blood flow 
compared to the peripheral choroid.16,17 These anatomical 
and functional choroidal differences, as well as anatomical 
differences between central and peripheral RPE and Bruch’s 
Table 3 VFQ-39 questionnaire scores of the study population and controls, and Pearson’s correlation with last visual acuity
VFQ-39 item Chronic CSC patients Controls Pearson’s correlation
Last visual acuity
Subjects Mean SD Subjects Mean SD P-value P-value
general health 36 65 17 122 75 17 -0.146 0.396
general vision 36 62 18 122 81 13 -0.36 0.031
Ocular pain 36 85 17 122 90 15 -0.044 0.8
near activities 36 72 23 122 93 10 -0.435 0.008
Distance activities 36 79 20 122 95 8 -0.475 0.003
social functioning 36 90 17 122 99 3 -0.416 0.012
Mental health 36 72 22 122 91 11 -0.509 0.002
Role difficulties 36 74 22 122 96 6 -0.628 ,0.001
Dependence 36 91 18 122 99 5 -0.408 0.013
Driving 31 70 29 122 89 14 -0.584 0.001
Color vision 36 94 19 122 98 8 -0.109 0.527
Peripheral vision 36 80 26 122 97 10 -0.178 0.299
Abbreviations: CsC, central serous chorioretinopathy; sD, standard deviation; VFQ, Visual Function Questionnaire.
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membrane,18,19 probably explain why CSC principally affects 
the posterior pole. However, it is currently unclear why some 
individuals develop active CSC in the case of a dysfunctional 
thickened choroid (“pachychoroid”) unlike others,20 and why 
in the same individual the disease can remain subclinical 
in the fellow eye despite the presence of similar choroidal 
abnormalities.5 It is likely that additional factors play a 
role in determining an individual’s likelihood to develop 
CSC, for instance, patient-specific differences in genetic 
background,7,8 local differences in RPE outer blood–retina 
function, and possibly the interphotoreceptor matrix.21
This studies data showed a marked decrease in reported 
vision-related quality of life in this cCSC cohort when 
compared to healthy individuals. Nevertheless, the impact 
of cCSC on vision-related quality of life seems to be less 
pronounced than in other common maculopathies, such as 
neovascular age-related macula degeneration and diabetic 
retinopathy.22,23 In this cCSC cohort, social functioning 
and dependence seemed to be most affected. Differences 
between the vision-related quality of life impact of the dif-
ferent diseases may not only be due to the variable effects on 
macular anatomy and visual function but may also be partly 
explained by the difference in the mean age of the different 
study populations during which the VFQ-39 questionnaire 
was taken (present study 55 years, neovascular age-related 
macular degeneration 77 years, diabetic retinopathy 68 years, 
and diabetic macular edema 62 years).23 Also, mean years 
since diagnosis was far shorter in the neovascular age-related 
macular degeneration studies compared to the present study 
(0.6 and 7.4 years). A possible explanation could also be 
that younger individuals are more flexible and capable of 
coping with newly developed visual impairment than older 
individuals.24 Also, the negative impact on reported vision-
related quality of life appears to be higher when evaluated 
closer to the onset of visual impairment.
Surprisingly, a significant difference in the reported 
quality of color vision was not found, although impaired 
color vision has been previously reported in CSC.25 It is still 
possible that disturbed color vision exists in this cohort, but 
that it remains subclinical, for example, due to a better-seeing 
fellow eye, and does not interfere with daily activities.
Conclusion
cCSC is a progressive chorioretinopathy, with many cCSC 
patients experiencing significant vision loss, lower vision-
related quality of life, and lower rating for overall health 
compared to healthy individuals. Despite these observa-
tions, it is not uncommon for ophthalmologists to adopt 
a conservative approach in these patients, who are often 
relatively young. The findings of this study demonstrate that 
the possible impact of cCSC should not be underestimated, 
and thus an active treatment approach may be advocated. 
However, few high-quality randomized controlled treat-
ment trials have been reported in cCSC, with a current lack 
of a gold standard for treatment of cCSC. We are currently 
performing a multicenter prospective randomized controlled 
treatment trial, comparing half-dose PDT with high-density 
subthreshold micropulse-laser treatment in cCSC (EudraCT 
2012-004555-36, NCT01797861) in an attempt to identify 
the most suitable treatment strategy in cCSC.
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